Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avastin for recurrent malignant ascites
NCT00908219Phase 2
Key facts
- Status
- Withdrawn
- Start
- Jul 2009
- Primary completion
- Feb 2011
- Countries
- 1
- Sponsor
- Baylor College of Medicine
- Modality
- Monoclonal Antibodies
- Drugs
- bevacizumab
- Conditions
- malignant ascites
01
Overview
Phase 2, open-label trial of bevacizumab in malignant ascites, sponsored by Baylor College of Medicine. Primary endpoint: Repeat paracentesis response rate at 12 weeks. Planned start Jul 2009; status: withdrawn.
02
Design
- Study design
- Non-randomizedOpen-labelSingle group
03
Who it enrols
Patients with persistent malignant ascites (positive cytology) who have failed diuretics and had at least two paracenteses, with ECOG 0-3 and no recent anti-VEGF or chemotherapy.
04
Endpoints
Primary
Repeat paracentesis response rate
Beyond the preview
Go deeper on NCT00908219.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00908219.